Soft Landing, Hard Numbers: Why a 57,000‑Job Economy May Love $RIVN, $SMWB, and $MODD

The market walked into June’s jobs report braced for a slowdown and still managed to be surprised by how leisurely the hiring pace has become—with a few high‑conviction growth stories quietly stealing the show in EVs, digital data, and med‑tech.

A “Goldilocks‑ish” Jobs Report Sets the Macro Stage

The US added 57,000 jobs in June, roughly half of what economists were expecting and a sharp downshift from May’s revised 129,000 gain. The unemployment rate, however, ticked down to 4.2%, its lowest level in a year, helped by a softer labor force participation rate and still‑muted layoffs. Professional and business services, social assistance, and healthcare did the heavy lifting, while leisure and hospitality actually shed 61,000 jobs amid weaker‑than‑usual seasonal hiring. Average hourly earnings rose about 3.5% year‑over‑year, a pace consistent with gradually cooling inflation rather than a wage‑price spiral. For equity investors, that mix—slower job creation, lower jobless rate, moderating wages—lands in the “slower but still standing” camp, reinforcing the case for a patient but ultimately more accommodative Fed rather than a policy emergency. In other words: macro headwinds are now more of a stiff breeze than a hurricane, which tends to favor stock pickers over index tourists..

Rivian’s Quiet Flex: Execution Over Hype

While the labor market eased off the accelerator, Rivian Automotive Inc. (NASDAQ:RIVN) used the quarter to demonstrate something that the EV space has been short on lately: consistent operational execution. The company produced 12,613 vehicles and delivered 12,194 units in Q2 2026, topping investor expectations and showing that its manufacturing ramp is becoming less of an experiment and more of a habit. Those results gave Rivian enough confidence to raise its 2026 delivery outlook to a range of 65,000–70,000 vehicles, up from a prior 62,000–67,000 forecast. The stock responded with a roughly 5% pop to around 18 dollars as investors rewarded the uncommon combination of volume growth, guidance discipline, and the prospect of operating leverage as the R2 platform ramps.

In a market that has punished EV hopefuls for over‑promising and under‑delivering, Rivian’s narrative is shifting from “story stock” to “execution story”—still high beta, but now with unit economics and guidance that increasingly have to be modeled rather than imagined. For portfolio managers, that’s the difference between a speculative flier and a name that can sit in an active growth sleeve with a thesis tied to tangible milestones: production scale, margin trajectory, and product mix.

Similarweb: Turning Data Exhaust into Durable ARR

If Rivian is about tangible steel and batteries, Similarweb Ltd. (NYSE:SMWB) is betting that digital exhaust—traffic, engagement, conversion patterns—is the new blue‑chip raw material for decision‑makers. The company announced that it has surpassed 300 million dollars in annual recurring revenue and signed two multi‑year enterprise contracts, each carrying seven‑figure ARR commitments. Collectively, those new deals represent about 47 million dollars in total contract value to be recognized over the next three years, and were inked during Q2 2026. Shares of Similarweb jumped roughly 12% to just under 5 dollars on the news, as investors recalibrated the company from “niche analytics provider” toward a scaled digital intelligence platform with growing enterprise stickiness. The strategic punchline is that these contracts are incremental to large deals deferred from late 2025, one of which was already signed in Q1 2026, reinforcing management’s confidence in the full‑year 2026 guidance. For growth‑oriented investors looking for under‑followed AI‑adjacent names, SMWB offers something of a rarity: a recurring‑revenue model built on data that customers increasingly view as mission‑critical, plus multi‑year visibility that can smooth out cyclical macro noise..

Modular Medical: From De‑Risking to Deployment

On the healthcare frontier, Modular Medical, Inc. (NASDAQ:MODD) is attempting to re‑write how insulin‑dependent patients experience daily therapy, and investors are starting to get a first look at real‑world commercialization. Following FDA 510(k) clearance in April for its Pivot tubeless insulin patch pump—a major de‑risking milestone—the company has now begun shipping Pivot starter kits to multiple endocrinology practices. The devices have initially headed to physician offices for training and early patient introductions, with a phased commercial rollout planned across select high‑volume practices and metropolitan markets through late 2026. Management has framed the opportunity as a way to convert the roughly 70% of insulin‑dependent adults who still rely on multiple daily injections because pumps have historically been too complex, cumbersome, or costly. With initial shipments underway and commercial availability declared, Modular Medical is effectively transitioning from a development‑stage med‑tech story to a commercial‑stage one, shifting the investor debate from “will they get approved?” to “how fast can they scale adoption?” For small‑cap healthcare specialists, MODD now screens as a leveraged play on a very large, very under‑penetrated diabetes technology market, with meaningful catalysts around adoption data and geographic expansion.

Where the Macro Meets the Micro for Investors

The June jobs report keeps the “soft landing” narrative intact, but with enough wobble to justify continued Fed vigilance and a gradual, data‑dependent path toward easier policy. That environment tends to reward companies that can create their own growth cycle—through execution, product differentiation, or long‑duration contracts—rather than relying on a roaring GDP backdrop to bail them out. Rivian (RIVN) is trying to become the EV player that hits its marks while peers miss; Similarweb (SMWB) is converting a secular data and AI tailwind into multi‑year ARR visibility; and Modular Medical (MODD) is stepping into revenue mode in a chronic‑care market where incumbency is strong but dissatisfaction is widespread. For investors navigating a slower‑growth, still‑elevated‑rate world, these are the kinds of names that can turn a “meh” macro tape into a portfolio that still has something to talk about at the next investment committee meeting.

The Sources

June jobs report: US payrolls rose by 57,000, missing expectations – Yahoo Finance
https://finance.yahoo.com/economy/article/june-jobs-report-us-payrolls-rose-by-57000-missing-expectations-190000748.html
US payrolls rose by 57,000 in June, missing expectations – Yahoo Canada Finance
https://ca.finance.yahoo.com/news/june-jobs-report-us-payrolls-rose-by-57000-in-june-missing-expectations-190000748.html
Jobs report June 2026 – CNBC
https://www.cnbc.com/2026/07/02/jobs-report-june-2026-.html
Employers added 57,000 jobs in June, far below forecasts – CBS News
https://www.cbsnews.com/news/june-jobs-report-57000-jobs-hiring-slows
US economy adds 57,000 jobs in June, below expectations – Yahoo Finance (video recap)
https://finance.yahoo.com/video/us-economy-adds-57000-jobs-in-june-below-expectations-123833694.html
Rivian raises 2026 delivery outlook while Lucid misses expectations – CNBC
https://www.cnbc.com/2026/07/02/rivian-lucid-q2-deliveries-demand.html
Rivian releases Q2 2026 production and delivery figures, raises full‑year outlook – Press release (Business Wire via Futu)
https://news.futunn.com/en/post/75459235/press-release-rivian-releases-q2-2026-production-and-delivery-figures
Rivian raises 2026 delivery forecast after stronger second‑quarter performance (RIVN) – Yahoo Finance
https://finance.yahoo.com/markets/stocks/articles/rivian-raises-2026-delivery-forecast-125225595.html
Rivian raises 2026 delivery guidance after Q2 beat – Grafa
https://grafa.com/en/news/united-states/rivian-q2-2026-deliveries-guidance-increase
Rivian tops Q2 delivery numbers and raises full‑year 2026 outlook – Electrek
https://electrek.co/2026/07/02/rivian-tops-q2-delivery-numbers-and-raises-full-year-2026-outlook
Rivian raises EV sales forecast as Q2 production ramps up – TechCrunch
https://techcrunch.com/2026/07/02/rivian-thinks-it-will-sell-more-evs-than-expected-this-year
Rivian is up 5% today: Is it outperforming other EV stocks like Tesla and Lucid? – 24/7 Wall St.
https://247wallst.com/investing/2026/07/02/rivian-is-up-5-today-is-it-outperforming-other-ev-stocks-like-tesla-and-lucid
Similarweb secures multi‑year, seven‑figure ARR contracts worth approximately $47 million – Business Wire
https://www.businesswire.com/news/home/20260615625728/en/Similarweb-Secures-Multi-Year-Seven-Figure-ARR-Contracts-Worth-Approximately-47-Million-in-Total-Contract-Value
Similarweb shares rise after new multi‑year contracts – MarketWatch
https://www.marketwatch.com/story/similarweb-shares-rise-after-new-multi-year-contracts-161a19c1
Modular Medical receives FDA 510(k) clearance for Pivot tubeless insulin patch pump – Nasdaq press release
https://www.nasdaq.com/press-release/modular-medical-receives-fda-510k-clearance-pivot-tubeless-insulin-patch-pump-2026-04
Modular Medical announces shipment of Pivot tubeless patch pumps – Morningstar / ACCESSWIRE
https://www.morningstar.com/news/accesswire/1181878msn/modular-medical-announces-shipment-of-pivot-tubeless-patch-pumps
Modular Medical announces commercial availability of Pivot tubeless insulin patch pump ahead of commercial expansion – The Globe and Mail (ACCESS Newswire)
https://www.theglobeandmail.com/investing/markets/markets-news/access-newswire/2624616/modular-medical-announces-commercial-availability-of-pivot-tubeless-insulin-patch-pump-ahead-of-commercial-expansion

by John F. Heerdink, Jr. July 2, 2026

Insulin, Algorithms, and Robin Hood: Why $HIMS, $HOOD, $MODD, $TNDM, and Investa Might Just Be The Smartest ‘Side Hustle’

Wall Street is quietly falling in love with a new pairing: precision insulin pumps, telehealth longevity medicine, and a Robin Hood‑style fintech model that lets users ride shotgun with the cap table. For investors, it’s a rare moment when diabetes devices, digital health, and retail options trading all hum the same tune: recurring revenue, regulatory momentum, and user engagement with teeth.

Diabetes Tech: Pumps Go Prime Time

In diabetes care, hardware is finally catching up to the software narrative. Modular Medical, Inc. (NASDAQ: MODD) has begun shipping its Pivot tubeless insulin patch pump starter kits to multiple endocrinology practices, moving from FDA clearance to practical deployment in a matter of weeks. The Pivot system is aimed squarely at “almost‑pumpers”—patients who’ve resisted legacy pump complexity—by marrying simplicity with patient‑centric design. Meanwhile, Tandem Diabetes Care, Inc. (NASDAQ: TNDM) continues to deepen its ecosystem with platforms like Tandem Source, a cloud‑based data hub that consolidates therapy data, remote uploads via the t:connect mobile app, and streamlined reporting for providers. For investors, this isn’t just UX polish; it’s infrastructure for higher stickiness, richer data, and a software‑like multiple in a historically hardware‑priced space.

From FDA Wins To Revenue Engines

The commercial arc is where the story gets interesting. Modular Medical’s FDA 510(k) clearance for Pivot in April 2026 set the regulatory foundation, but the June shipment of starter kits into endocrinology practices marks the shift from “promise” to “pipeline.” The company plans a phased rollout, focusing first on high‑volume practices and select metropolitan markets by late 2026—effectively converting clinical champions into regional demand hubs. Tandem’s strategy leans into scale and data gravity. By migrating users and clinicians onto Tandem Source, TNDM is building a single pane of glass for insulin pump data, supply reorders, and software updates, creating a fertile ground for future decision‑support tools and potential AI‑enabled insights. What’s the possible upshot? MODD offers early‑stage adoption optionality, while TNDM builds a more mature platform that could justify an evolving revenue mix beyond hardware.

Telehealth Grows Up: HIMS Bets On Longevity

Digital health, once synonymous with “hair loss ads between podcasts,” is pivoting into serious medicine. Hims & Hers Health, Inc. (NYSE: HIMS) recently appointed Dr. Anant Vinjamoori as Chief Medical Officer of the Hims brand, a role that extends across sexual health, hormone health, dermatology, weight management, mental health, and emerging longevity and peptide therapies. Dr. Vinjamoori brings more than a decade of experience in internal medicine, primary care, longevity medicine, and digital health leadership, positioning HIMS to tighten clinical rigor as it expands into prevention‑oriented and higher‑acuity categories. For a company often caricatured as “telehealth with good marketing,” this is a deliberate move up the medical value chain—where outcomes matter, churn drops, and ARPU has room to run.

Platform Risk Meets Clinical Credibility

HIMS’s appointment also speaks to a broader investor theme: platform risk versus platform trust. As telehealth expands into weight loss, mental health, and peptide‑based therapies, regulatory attention and clinical scrutiny naturally sharpen, making medical leadership a key piece of the investment mosaic. By integrating longevity medicine and peptide therapy under a unified medical strategy, HIMS is effectively signaling to markets that it wants to be seen less as a convenience brand and more as a scaled care delivery platform. For equity holders, that raises both expectations and potential multiples: higher‑stakes medicine, but also higher‑stakes valuation.

Fintech With A Cape: Investa’s Robin Hood Moment

Over in London, Investa is trying a different form of disruption: changing who gets paid when a platform succeeds. The UK‑based investment platform, founded by options specialist Alec Beasley, has launched a “Robin Hood (HOOD) Rewards” initiative that will grant more than 3,000 of its most active users options in the company worth up to £1,000 at its last £10 million valuation..The programme is designed as a first‑of‑its‑kind reward model in the UK, giving early users a direct financial stake in Investa’s future growth and later expanding into a referral system where both existing and new users can earn company options tied to platform performance. In a market where loyalty has typically enriched only shareholders, Investa is trying to narrow the gap between “product user” and “equity participant,” effectively turning customers into a distributed, incentive‑aligned sales force.

Options For The Masses, Optionality For Investors

Investa’s core mission is to make options trading more accessible for UK retail investors, layering education and product access over a still‑intimidating asset class. By adding equity‑linked rewards on top, the platform is playing a double‑optional game: options trading for users, equity options for loyalty, and potential growth optionality for future investors if the model scales. For professional investors watching from the sidelines, the experiment is worth tracking less for near‑term P&L and more as a signal of how fintech may evolve: user acquisition that doesn’t just reward engagement with points or cashbacks, but with genuine slices of upside. If the structure navigates regulatory scrutiny and proves economically durable, it could become a template for smaller, early‑stage platforms aiming to punch above their paid‑marketing weight.

The Common Thread: Ownership, Data, And Stickiness

Across MODD, TNDM, HIMS, and Investa, a handful of themes keep reappearing: user ownership, data leverage, and product stickiness.[investing]

In diabetes tech, MODD’s Pivot and TNDM’s Tandem Source are about giving patients and clinicians more control and insight, turning devices into connected, feedback‑rich ecosystems.
In telehealth, HIMS is extending into longevity and peptide‑based care with a stronger medical spine, aiming to keep patients in the platform as their health needs evolve over time.
In fintech, Investa’s Robin Hood Rewards flips customer loyalty into cap table participation, betting that shared upside is the stickiest retention mechanism of all.

For investors, these are not just product stories—they are business model stories, where recurring engagements and rising data moats can compound quietly underneath the headline product launches.

Where The Opportunity May Reside

None of these names sits neatly in the old sector boxes. MODD and TNDM live at the crossroads of medtech and software; HIMS straddles consumer brand, telehealth, and longevity; Investa blends retail trading with platform economics and customer equity. For fundamental investors, the work now is less about reading the press releases and more about mapping their implications: adoption curves for Pivot, margin evolution as Tandem Source deepens, retention and LTV as HIMS adds more medically intensive services, and user behaviour as Investa turns customers into co‑owners. It is, in short, an environment where a bit of sophisticated skepticism is warranted—but so is a willingness to acknowledge that some of the most interesting equity stories are emerging where medicine, software, and ownership intersect.

The Sources

Here’s a clean, numbered list of the key sources and links relevant to the story we built, in simple SEO‑friendly format:

Tandem Diabetes Care, Inc. (TNDM) – Tandem Mobi & Tandem Source
https://investor.tandemdiabetes.com/news-releases/news-release-details/tandem-diabetes-care-launches-tandem-mobi-worlds-smallest
https://investor.tandemdiabetes.com/news-releases/news-release-details/tandem-diabetes-care-announces-full-us-launch-tandem-source
Modular Medical, Inc. (MODD) – Pivot Tubeless Patch Pump & Shipments
https://www.stocktitan.net/news/MODD/modular-medical-receives-fda-510-k-clearance-for-pivot-tubeless-h2yibgu7uc0k.html
https://www.morningstar.com/news/accesswire/1181878msn/modular-medical-announces-shipment-of-pivot-tubeless-patch-pumps
Modular Medical CEO Event – Tribe Public / Vista Partners
https://www.youtube.com/watch?v=qnVc1JL2jyc
Hims & Hers Health, Inc. (HIMS) – Appointment of Dr. Anant Vinjamoori, CMO
https://www.investing.com/news/company-news/hims–hers-appoints-dr-anant-vinjamoori-as-chief-medical-officer-93CH-4726785
https://www.nasdaq.com/articles/hims-hers-names-anant-vinjamoori-cmo-hims-brand
https://www.citybiz.co/article/855853/hims-hers-appoints-dr-anant-vinjamoori-as-chief-medical-officer-of-hims/
https://www.sahmcapital.com/news/content/how-investors-are-reacting-to-hims-hers-health-hims-hiring-a-longevity-focused-chief-medical-officer-news
Investa – “Robin Hood Rewards” Initiative
https://ffnews.com/newsarticle/investa-launches-robin-hood-rewards-initiative-for-user
https://markets.businessinsider.com/news/stocks/investa-launches-robin-hood-rewards-initiative-for-users-to-share-in-its-future-success-2024-6-1064072852

by John F. Heerdink, Jr. July 1, 2026

July 1, 2026 – Dow Nears Record, Nasdaq Sulks: Warsh Talks Inflation While META Monetizes Machine Mojo -( $AMWL $EPRX $LIME $META $MODD $SMWB $SPCX Rise! )

US stocks opened the second half on a mixed footing Wednesday, with the Dow Jones Industrial Average inching near record territory before retreating slightly, while the Nasdaq Composite slipped as investors rotated out of mega-cap tech and digested fresh commentary from Federal Reserve Chair Kevin Warsh on the path of inflation and rates.

Market wrap: mixed start to H2

The Dow Jones Industrial Average finished roughly flat, down .03%, after briefly touching a new record intraday as gains in select industrial, financial, and energy components offset tech softness.
The S&P 500 dropped by .22%, but was somewhat supported by cyclicals and value-oriented sectors even as growth and high-multiple tech came under pressure.
The Nasdaq Composite declined .66%, weighed by profit‑taking in AI leaders and a cautious reaction to Fed communication, reinforcing the sense that big tech may be entering a digestion phase after a powerful first-half run.

For investors, the tape signaled a nuanced handoff into the back half of 2026: equity indices remain supported by resilient earnings and steady growth, but leadership is broadening beyond the AI complex as markets re-price the odds of further tightening.

Macro & Fed: Warsh tries to thread the needle

Fed Chair Kevin Warsh used a closely watched policy forum to argue that upside inflation risks have “eased somewhat” but remain uncomfortably above the Federal Reserve’s 2% objective, keeping additional rate hikes squarely on the table if progress stalls. Recent labor data showing robust job openings and firm wage dynamics have reinforced the case for maintaining a restrictive stance for longer, with futures markets now pricing a slower and shallower easing cycle than they anticipated earlier in the year..

At the same time, Warsh acknowledged growing signs of policy fatigue, noting that tighter financial conditions, a softer housing impulse, and tentative cracks in consumer credit warrant a more data‑dependent approach rather than pre‑committing to a preset hiking path. For markets, the key takeaway is that the Fed appears content to keep rates elevated while watching the lagged impact of past hikes filter through, rather than rushing either to cut or to tighten aggressively, which helps anchor the front end of the curve but leaves longer‑dated yields sensitive to each incremental inflation print.

Sector moves and leadership rotation

Technology & communication services: Large‑cap tech and AI hardware names underperformed, with the Nasdaq’s decline reflecting rotation away from the year’s most crowded leadership. Investors appeared to fade some of the strongest first‑half winners ahead of a dense Q2 earnings calendar and amid concern that higher‑for‑longer policy could pressure valuation multiples.
Financials and cyclicals: Bank and broker‑dealer shares caught a bid on the back of a steeper yield curve and the prospect that a still‑resilient economy will support credit quality and fee pools, while industrial and materials stocks benefited from ongoing evidence of steady global demand.
Energy and commodities: Crude oils prices hovered just below 68 dollars per barrel, leaving the energy complex broadly supported but not exuberant, as investors weigh Middle East geopolitical risks against a modestly cooling global growth outlook. Meanwhile, gold close above below 4,000 dollars per ounce as the firmer rate narrative and stronger dollar dented demand for defensive hedges.

This mix of sector outcomes underscores a market that is still constructive on growth but increasingly selective, rewarding cash‑generative cyclicals and high‑quality financials while forcing investors to be more valuation‑sensitive in high‑beta growth and AI narratives.

Single‑stock drivers: META, SpaceX and Lime

Meta Platforms (META): Shares surged as much as about 9% after the company announced a new push to monetize and resell excess AI compute capacity through a cloud‑style offering, effectively positioning Meta as both a hyperscale AI consumer and an infrastructure supplier. The strategy builds on its recent multiyear agreements to secure advanced GPU capacity and aims to improve returns on capital‑intensive data center investments by creating a recurring revenue stream from third‑party AI workloads. For investors, the move reinforces the idea that META is evolving from a pure‑play digital ad platform into a broader AI infrastructure and services business, potentially supporting multiple expansion if execution is strong.
SpaceX (SPCX): A high‑profile tech analyst initiated coverage of SpaceX with an Outperform‑style rating and a 190 dollar price target, arguing that the company’s integrated launch and satellite broadband model provides a durable competitive moat and a multi‑trillion‑dollar total addressable market over time. While SpaceX is not yet publicly listed, the call is likely to further fuel investor enthusiasm for space‑economy adjacencies and could have read‑through for publicly traded suppliers and partners in launch hardware, satellite components, and ground infrastructure ecosystems.
Lime (LIME): Newly public micromobility operator Lime opened trading at 27 dollars per share following its IPO, which was priced at a discount to that level and framed by management as having “landed at the right moment” given supportive risk appetite and improving unit economics. The deal’s reception may be viewed as a litmus test for investor appetite toward consumer‑facing, growth‑oriented listings after a multi‑year drought in high‑beta IPO activity, and early trading will be closely watched for signs that the window is re‑opening for similar capital‑intensive platform stories.

Positioning takeaways for investors

Expect more two‑way macro volatility: With the Fed signaling patience but not victory, each incremental inflation, jobs, and wage print will carry outsized influence on both yields and equity multiples, arguing for maintaining a balanced risk posture and avoiding one‑way bets on imminent cuts.
Lean into quality within cyclicals and financials: As leadership broadens beyond the AI complex, high‑quality banks, insurers, and industrials with strong balance sheets and pricing power may offer attractive risk‑adjusted exposure to a still‑resilient nominal growth backdrop.
Stay selective in AI and tech: META’s cloud‑style AI compute initiative highlights that the AI narrative is shifting from pure infrastructure build‑out to monetization and services, favoring platforms that can capture recurring, differentiated revenue streams over commodity hardware exposure. Investors may want to tilt toward companies with clear pathways to cash flow from AI, rather than simply scale in parameter counts or capex alone.

VP Watchlist Updates

Amwell® (NYSE: AMWL)

Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $9.37, +2.74%.

Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals Inc. (EPRX, $6.71, +1.51%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”

Modular Medical, Inc. (NASDAQ: MODD)

Modular Medical, Inc. (NASDAQ: MODD, $4.68, +4%), a leader in innovative, patient-centric insulin delivery, today (June 30) announced that the first patients have completed onboarding and training and are now actively using the Pivot™ tubeless insulin patch pump in real-world settings. This milestone marks the transition of the Pivot pump from development into active patient use and represents a significant step in Modular Medical’s commercialization strategy. The Company will now begin collecting real world utilization data and user feedback to support broader adoption and continued product deployment optimization.

MODD announced ( June 26) that the Pivot™ tubeless insulin patch pump is now shipping to physician offices for training. Upon completion of training, these pumps will be presented to potential patients in the next few days and weeks. The Company intends to expand the roster of practices that offer Pivot over the coming months. This is another significant milestone in the deployment of Pivot. Modular Medical looks forward to updating the market when these first patients are using the pump to deliver insulin. The Pivot pump is purpose-built for adults with diabetes on daily injections who have faced cost, complexity, and usability barriers with traditional pump systems. This group represents an estimated 70% of insulin-dependent adults who remain on multiple daily injections, a multi-billion-dollar opportunity within the diabetes technology market.

MODD announced (June 24) that the Pivot™ tubeless insulin patch pump is now commercially available. This marks the start of real-world patient use, and the Company’s transition to a commercial-stage medical device company. As only the second fully electronic, tubeless insulin pump available in the United States, Pivot is designed to make pump therapy simpler to learn and easier to live with. Its removable two-part design and 3 mL reservoir, intuitive interface, and flexible, wearable form factor support everyday activities, such as showering and sports, with no battery recharging required – all while maintaining clinical accuracy and connectivity. “Reaching commercial availability is a transformational milestone that marks Modular Medical’s transition from a development-stage company to a revenue-generating commercial business,” said Jeb Besser, Chief Executive Officer of Modular Medical. “As only the second fully electronic tubeless pump on the U.S. market, Pivot is positioned to serve a large, underserved ‘almost-pumper’ population. With first shipments beginning this week, we are focused on disciplined execution, as we scale adoption and seek to build long-term value for patients and shareholders.”

On (June 4) the launch of PivotPump.com, a patient-focused website designed to support individuals seeking a simpler path to insulin pump therapy. This launch follows the Company’s receipt of U.S. Food and Drug Administration (“FDA”) clearance in April 2026 for its Pivot™ insulin delivery system. The FDA clearance represents a significant milestone in Modular Medical’s strategy to expand access to insulin pump technology, particularly among individuals historically underserved by existing solutions. The Company remains on track for commercial launch in the fall of 2026. Pivot is designed for people living with diabetes who rely on daily insulin injections, as well as those who have encountered technological, usability, or cost-related barriers with traditional pump systems. The system emphasizes simplicity and ease of use for the patient and full access to clinical information for the clinician to reduce adoption friction. The PivotPump.com website provides accessible, educational content on insulin pump therapy and highlights the Company’s focus on real-world usability and supporting patients in evaluating and adopting pump-based diabetes care.

Similarweb Ltd. (NYSE: SMWB)

Similarweb Ltd. (NYSE: SMWB, $6.50, +7.50%), a leading digital data and analytics company powering critical business decisions, announced (June 15) that it has surpassed $300 million in Annual Recurring Revenue (ARR) and signed two multi-year enterprise contracts, each representing seven-figure ARR commitments. Collectively, these contracts represent approximately $47 million in Total Contract Value to be recognized over the next three years and were signed during the second quarter of 2026.

NVIDIA (NVDA)

NVIDIA (NVDA) closes at $197.58,-1.25%.

Rocket Lab Corporation (Nasdaq: RKLB)

Rocket Lab Corporation (Nasdaq: RKLB, $100.07), a global leader in launch and space systems and Iridium Communications Inc. (Nasdaq: IRDM, $54.85, +24.21% over the last 5-days) a leading provider of global voice, data, and positioning, navigation, and timing (PNT) satellite services, announced (June 29) they have entered into a definitive agreement under which Rocket Lab will acquire Iridium. Rocket Lab will acquire all the outstanding shares of Iridium common stock for $54 per share in a cash and stock transaction. This represents an enterprise value for Iridium of approximately $8.0 billion.

The InterGroup Corporation (NASDAQ: INTG), a diversified holding company with interests in hospitality, real estate, and marketable securities. InterGroup consolidates its majority‑owned subsidiary Portsmouth Square, Inc., which owns the Hilton San Francisco Financial District hotel and related facilities, closed at $46.

The Sources

Yahoo Finance – “Stock market today: Nasdaq dips, Dow and S&P 500 rise as markets weigh Kevin Warsh’s remarks”
https://finance.yahoo.com/markets/live/stock-market-today-nasdaq-dips-dow-and-sp-500-rise-as-markets-weigh-kevin-warshs-remarks-224748322.html
CNBC – “Live: Dow closes little changed after touching record; Nasdaq slides to start July”
https://www.cnbc.com/2026/06/30/stock-market-today-live-updates.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
Yahoo Finance – “Lime opens at $27 a share, IPO happened at the right moment, CEO says”
https://finance.yahoo.com/markets/stocks/article/lime-opens-at-27-a-share-ipo-happened-at-the-right-moment-ceo-says-162509539.html
Yahoo Finance – “Tech bull Ives initiates SpaceX with outperform rating, $190 price target”
https://finance.yahoo.com/markets/stocks/article/tech-bull-ives-initiates-spacex-with-outperform-rating-190-price-target-145826109.html
Yahoo Finance – “Inflation risks eased, Fed chair says”
https://finance.yahoo.com/economy/policy/articles/inflation-risks-eased-fed-chair-195646286.html
CNBC – “Meta pops 9% as company makes cloud push to sell excess AI compute capacity”
https://www.cnbc.com/2026/07/01/meta-stock-cloud-ai-compute.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard

by John F. Heerdink, Jr. July 1, 2026

Cooler Jobs, Hotter Trades: What A Sub‑100K Payroll Print Can Mean For Your Risk Book-( $LLY $MODD $SMWB $TSM )

Wall Street is tiptoeing into summer with inflation still in the doghouse, jobs growth cooling just enough to keep the Fed interesting, and a trio of stock-specific storylines reminding investors that stock-picking still matters in an index world.

Key Takeaways For Investors

The Fed remains rhetorically welded to a 2% inflation target, keeping “higher for longer” very much alive even as growth cools.
Private payroll gains are slowing, which supports the case for rate cuts later this year but also underscores a late-cycle feel.
Select growth names in semis, specialty diabetes tech, and digital intelligence platforms are still winning budget share and analyst mindshare, offering pockets of upside in a choppy tape.

The Fed’s 2% Line In The Sand

The Fed’s Kevin Warsh has effectively reminded markets that 2% inflation is not a polite suggestion but the central bank’s institutional hill to die on. His message: the Fed will not be “comfortable” with inflation north of 2%, even if the labor market softens and political pressure to ease mounts.

For investors, that implies the bar for rapid, aggressive rate cuts remains high, and the Committee is more likely to trade a bit more unemployment for credibility than the other way around. The market’s favorite fantasy—persistent growth, easing inflation, and quick cuts—still exists, but Warsh’s comments are a reminder that the Fed’s reaction function is anchored in price stability first and asset prices a distant second.

Jobs: Cooling, Not Cracking

Fresh private payroll data showed that employers added fewer jobs than expected in June, clocking in at under six figures and signaling that the labor market is moving from “red‑hot” to merely “warm.” It is not a recession print, but it does take a little shine off the “no‑landing” narrative that had crept into risk assets earlier this year.

For the Fed, a softer print offers political and analytical cover to ease later in the year if inflation continues to trend toward target. For investors, it bolsters the “carry and quality” regime: higher front‑end yields remain attractive, but so do large‑cap compounders with pricing power who can navigate a slower, but not collapsing, demand backdrop.

Semis Still Steal The Macro Show: TSMC And Lilly

Even on a data-heavy day, equity leadership is still being written in 7‑nanometer script. Taiwan Semiconductor Manufacturing Co. Ltd. (TSM) continued to attract positive analyst attention, with at least one major firm upgrading the stock and highlighting the company’s central role in the AI and high‑performance compute build‑out.

At the same time, Eli Lilly and Co. (LLY) remains a bellwether for the “health‑span” trade, with its obesity and diabetes franchises anchoring long‑duration growth expectations and drawing renewed buy‑side conviction. The pairing of TSM and LLY on upgrade radars underscores a durable theme: markets continue to reward platforms that sit at the intersection of structural demand (AI infrastructure and metabolic health) and genuine pricing power.

Modular Medical: A Small‑Cap Shot Of Insulin Innovation

Modular Medical, Inc. (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery technology, today announced submission to the U.S. Food & Drug Administration (FDA) of a series of software enhancements to its PivotTM insulin delivery system, providing users with more customization options and user-interface (UI) improvements, as well as other software upgrades.

“This submission is the first of a series of further improvements and upgrades planned for the Pivot platform, now that our core form factor has been cleared by the FDA and is in the market. I want to congratulate our whole team for getting this submission in so quickly after the initial Pivot clearance,” said Jeb Besser, Chief Executive Officer of Modular Medical. “We look forward to getting feedback from the FDA in the coming weeks.”

For more information on the Pivot system, visit the dedicated site PivotPump.com.

Similarweb: Data As A Line Item, Not A Nice‑To‑Have

Digital intelligence provider Similarweb Ltd. (SMWB) secured a multi‑year, multi‑seven‑figure agreement with a “leading multinational tech company,” an announcement that reads like a quiet but important vote of confidence in the company’s data and platform. The fact that a large technology customer is willing to sign up for a multi‑year budget commitment reinforces the idea that third‑party digital analytics are becoming infrastructure, not discretionary spend.[

For investors, the deal checks several boxes at once: validation of SMWB’s enterprise value proposition, improved revenue visibility, and leverage to secular growth in data‑driven decision‑making across marketing, product, and strategy teams. In a macro tape still fretting about IT budgets, landing a multi‑seven‑figure subscription is a helpful rebuttal to the “every SaaS tool is negotiable” narrative.

How To Position Now: Quality Growth, Select Small‑Cap Optionality

The current setup—Fed still hawkish on inflation optics, labor cooling but not cracking, and alpha concentrated in genuine platforms—argues for a barbell.

On one side, large‑cap quality such as Taiwan Semiconductor (TSM) and Eli Lilly (LLY), which combine secular growth with balance‑sheet strength.
On the other, selectively under‑followed innovators like Modular Medical (MODD) and execution‑sensitive digital platforms like Similarweb (SMWB), where idiosyncratic catalysts can matter more than the next dot on the Fed’s SEP.

In between, investors can still harvest attractive yields in front‑end fixed income while using equity exposure to express views on AI infrastructure, metabolic health, and data monetization rather than on the precise timing of the next rate cut. As Kevin Warsh might put it, the Fed is not in the business of optimizing your Sharpe ratio—so you may as well own businesses that can do a little of that for you.

The Sources

1. Kevin Warsh / Fed on inflation staying above 2% – Yahoo Finance Policy & Economy article.
https://finance.yahoo.com/economy/policy/article/kevin-warsh-fed-will-not-be-comfortable-with-inflation-above-2-183000837.html

2. Modular Medical, Inc. (MODD) announcesl FDA submission – Yahoo Finance Healthcare article.https://finance.yahoo.com/healthcare/articles/modular-medical-announces-fda-submission-115600373.html

3. Similarweb Ltd. (SMWB) secures multi–seven‑figure deal – Yahoo Finance Markets / Stocks article https://finance.yahoo.com/markets/stocks/articles/similarweb-secures-multi-seven-figure-120000712.html

4.Private employers added fewer jobs than expected in June – Yahoo Finance Economy article. https://finance.yahoo.com/economy/article/private-employers-added-98000-jobs-in-june-fewer-than-expected-122106116.html

5.Taiwan Semiconductor Manufacturing Co. (TSM) and Eli Lilly (LLY) analyst actions – Yahoo Finance Markets / Stocks article.https://finance.yahoo.com/markets/stocks/articles/taiwan-semiconductor-upgraded-eli-lilly-192544131.html

by John F. Heerdink, Jr. July 1, 2026

When Simplicity Becomes a Moat: How Modular Medical’s Pivot Pump Could Reprice Diabetes Convenience -( $ABT $MODD $LLY )

Modular Medical’s (NASDAQ: MODD) latest FDA submission turns a quiet diabetes niche into a live‑wire medtech story, with an underappreciated, tubeless insulin “Pivot” that is starting to look less like a gadget and more like a platform.

A Small Cap With Big Ambitions: Modular Medical Tries to Pivot Diabetes Care

On most trading days, insulin pumps don’t exactly compete with AI chips or meme stocks for screen time. Yet Modular Medical, Inc. (NASDAQ: MODD) is quietly scripting a different storyline, one FDA submission at a time, around its Pivot tubeless insulin patch pump.

The company’s latest move—a fresh software‑enhancement submission to the U.S. Food & Drug Administration—nudges Pivot further from “interesting device” toward “scalable diabetes delivery platform,” with an eye on the millions of “almost pumpers” still managing their disease with multiple daily injections.

The News: FDA Submission Signals a Platform, Not a One‑Off

Modular Medical announced that it has submitted a package of software enhancements for its Pivot insulin delivery system to the FDA, targeting more patient flexibility, customization and user‑interface refinements.

Management framed the filing as the first in a planned series of iterative improvements now that the core Pivot form factor has been cleared and has entered the U.S. market, with the company expecting feedback from the agency in the coming weeks. That cadence matters for investors: a small‑cap medtech name signaling that the hard part—initial clearance—is done, and the roadmap now is about product refinement, feature velocity and market penetration.

Why Pivot Exists: Solving for Simplicity, Not Just Sensors

Most of the insulin‑pump arms race has been waged at the high end, catering to tech‑savvy, highly engaged patients willing to navigate complex UIs, tight software ecosystems and long‑term device commitments. Modular Medical’s founding thesis is almost the opposite: the real white space sits with the majority of people still on multiple daily injections who find traditional pumps too expensive, too complicated or both.

Pivot is explicitly designed as a tubeless, intuitive insulin delivery solution meant to fit into normal life—“no tubes, no long‑term contracts, no tech overwhelm,” as the company describes it—so that patients can get the benefits of pump therapy without feeling like they’ve taken on a part‑time IT job.

How Pivot Works: A Pump Built for Real Life

From a user’s perspective, Pivot is engineered to be closer to “set and go” than “read the manual.”

Patients fill a 300‑unit cartridge with rapid‑acting insulin and attach it to the compact pump body.
Using an inserter, they place the infusion set on the chosen site, then snap on the pump.
An individualized basal rate runs in the background, while boluses are delivered with a single button press—no elaborate menu diving required.
The device is designed to be removable and re‑attachable so users can manage everyday activities while maintaining A1C and time‑in‑range targets.

Under the hood, Pivot uses a three‑piston diaphragm pump architecture that emphasizes precise micro‑dosing and isolates the insulin reservoir from the patient, a design intended to reduce the risk of accidental overdosing while maintaining consistent delivery. For diabetics and investors alike, that combination—simple on the outside, engineered on the inside—is where the value creation potential sits.

Watch the Story: Founder’s Rationale in Focus

For those who prefer their due diligence with visuals, the company has leaned into video to explain its origin story and product philosophy, including a feature segment that showcases why Pivot was built and how it aims to simplify day‑to‑day diabetes management.

You can watch a highlighted discussion of the Pivot pump’s design, ease of use and intended patient profile here: Modular Medical – Pivot Pump Video. The video underscores a simple message: diabetes therapy doesn’t need more bells and whistles; it needs to be less of a burden.

Market Context: “Almost Pumpers” as a Structural Growth Theme

Modular Medical’s own filings describe it as an early commercial‑stage diabetes device company, targeting a large population of so‑called “almost pumpers”—patients who have not yet crossed the adoption chasm from injections to pumps.

The Investment Angle: Optionality in a Small Package

For investors scanning medtech for asymmetric payoffs, the Modular Medical setup has a few notable features.

A focused FDA Cleared product: Pivot doesn’t pretend to be all things to all patients; it targets simplicity and accessibility for a large, under‑served cohort.
Regulatory momentum: The first‑wave 510(k) submission for the Pivot tubeless pump and the new software‑enhancement filing suggest an iterative, platform‑style approach rather than a single binary catalyst.
Execution leverage: With validation manufacturing lots underway and a commercial launch roadmap in motion and incremental regulatory progress may translate directly to commercial inflection.

Of course, this is still a small, early commercial‑stage name in a competitive space, which means execution risk, reimbursement dynamics and real‑world adoption all matter as much as engineering elegance. But when a company designs a device that lets people manage diabetes without feeling like they’ve enrolled in a graduate program in endocrinology, markets tend to pay attention over time.

Bottom Line: A “Simple” Pump That Could Complicate the Competitive Landscape

Modular Medical is not trying to win the next gadget contest; it is trying to win the next cohort of patients who have never had a pump at all. With its latest FDA submission, the company is signaling that Pivot is a living, upgradable platform aimed at making insulin therapy less intimidating and more broadly available.

For investors, that combination of regulatory momentum, product simplicity and a large under‑penetrated patient base is exactly the kind of quietly compounding narrative that can move from the small‑cap page to the front section and possibly on the radar of massive diabetes players i.e. Eli Lilly (LLY) or Abbott (ABT) —sometimes faster than the market expects.

The Sources

[1] Modular Medical Announces FDA Submission of Pivot Tubeless Insulin Patch Pump Enhancements https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/modular-medical-announces-fda-submission-of-pivot-tubeless-insulin-pa-1184860
[2] About – Pivot Pump https://pivotpump.com/about
[3] [10-K] Modular Medical, Inc. Files Annual Report https://www.stocktitan.net/sec-filings/MODD/10-k-modular-medical-inc-files-annual-report-59393142df7c.html
[4] Modular Medical hits validation milestone, targets commercial launch for insulin patch pump soon https://www.drugdeliverybusiness.com/modular-medical-validation-milestone-pivot/
[5] Modular Medical Announces FDA Submission of Pivot Tubeless Insulin Patch Pump Enhancements https://www.theglobeandmail.com/investing/markets/markets-news/ACCESS%20Newswire/3074556/modular-medical-announces-fda-submission-of-pivot-tubeless-insulin-patch-pump-enhancements/
[6] Modular Medical submits software enhancements for Pivot system to FDA https://www.investing.com/news/company-news/modular-medical-submits-software-enhancements-for-pivot-system-to-fda-93CH-4770258
[7] Modular Medical Submits Pivot Tubeless Insulin Patch Pump for … https://www.nasdaq.com/press-release/modular-medical-submits-pivot-tubeless-insulin-patch-pump-fda-510k-clearance-2025-11
[8] Diabetes Management Simplified | Modular Medical – YouTube https://www.youtube.com/watch?v=SaPywoFMBEg
[9] Modular Medical submits software enhancements for Pivot system to FDA https://www.investing.com/news/company-news/modular-medical-submits-software-enhancements-for-pivot-system-to-fda-93CH-4770258
[10] Envoy Medical submits first module of PMA to FDA for implant https://www.investing.com/news/company-news/envoy-medical-submits-first-module-of-pma-to-fda-for-implant-93CH-4767886
[11] Modular Medical hits validation milestone, targets commercial launch for insulin patch pump soon https://www.drugdeliverybusiness.com/modular-medical-validation-milestone-pivot/
[12] Modular Medical seeks FDA sign-off for Pivot pump customization upgrades https://www.stocktitan.net/news/MODD/modular-medical-announces-fda-submission-of-pivot-tubeless-insulin-ucywmyvy0jgt.html
[13] Modular Medical Announces FDA Submission of Pivot Tubeless Insulin Patch Pump Enhancements https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/modular-medical-announces-fda-submission-of-pivot-tubeless-insulin-pa-1184860
[14] Envoy Medical Submits First Module of Modular Premarket Approval Application to the U.S. Food and Drug Administration for Breakthrough-Designated Device https://www.newsfilecorp.com/release/303387/Envoy-Medical-Submits-First-Module-of-Modular-Premarket-Approval-Application-to-the-U.S.-Food-and-Drug-Administration-for-BreakthroughDesignated-Device
[15] Envoy Medical submits first module of PMA to FDA for implant https://www.investing.com/news/company-news/envoy-medical-submits-first-module-of-pma-to-fda-for-implant-93CH-4767886
[16] [PDF] September 4, 2024 Modular Medical, Inc. Kelsie DiPerna Sr … https://www.accessdata.fda.gov/cdrh_docs/pdf24/K240158.pdf
[17] NEW Modular Insulin Pump – MODD-1 Explained https://www.youtube.com/watch?v=6ABx0uPBoQ8

by John F. Heerdink, Jr. June 30, 2026

The ‘Almost‑Pumper’ Revolution: Modular Medical’s Pivot And The Art Of Making Diabetes Easier -( $MODD )

Modular Medical’s Pivot™ tubeless insulin patch pump is quietly staging the kind of commercial debut that makes both endocrinologists and investors sit up a little straighter. With first patients now trained and actively dosing in the wild as of this week, the company has begun its transition from R&D promise to revenue reality.

Insulin, Simplified: A Commercial Debut With Stakes

In late June, Modular Medical announced that its Pivot tubeless insulin patch pump is now commercially available in the U.S. following FDA 510(k) clearance in April, formally marking its move into commercial-stage territory. The rollout begins with shipments of starter kits to multiple endocrinology practices, where adults on multiple daily injections (MDI) are completing training and starting real-world use of the device. Pivot is positioned as the second fully electronic, tubeless insulin pump, on the U.S. market, explicitly designed with key ‘easy to use’ advantages to target the large, underserved “almost‑pumper” population that has resisted traditional, high-friction pump platforms. That cohort—millions of insulin‑dependent adults still reaching for syringes and pens—represents a multibillion‑dollar revenue opportunity if simplicity, affordability, and outcomes can finally coexist in one platform.

From Daily Injections to Push‑Button Control

The Pivot experience begins with a familiar clinical ritual: filling a cartridge with 300 units of rapid-acting insulin and snapping it into the small, wearable pump. An inserter guides the infusion set to the chosen site, after which the pump attaches and quietly assumes the role of basal workhorse in the background. Bolus delivery is triggered by a single button press, aiming to replace the stop‑and‑calculate choreography of multiple daily injections with discreet control and continuous coverage. Modular Medical emphasizes that Pivot was created for everyday life rather than gadget enthusiasts, with a design that can be removed and reattached as needed—showering, sports, or workdays included—without the burden of cables or battery charging cycles. The company’s messaging stresses that patients do not need to be “perfect” or highly tech‑savvy to manage their diabetes better, a subtle but important shift away from feature‑heavy systems toward pragmatic consistency.

A Tubeless Bet On the “Almost‑Pumper”

Most advanced diabetes technology historically catered to a narrow slice of motivated, well‑insured patients willing to climb a steep learning curve. Pivot was built explicitly to invert that paradigm, offering a tubeless insulin solution meant to remove complexity rather than showcase it. Modular Medical’s platform targets adults with type 1 or type 2 diabetes who have hesitated to adopt pumps—often due to cost, training demands, and the perception that pump therapy is a lifestyle rather than a tool. With Pivot, the company is betting that simplicity, discretion, and connectivity—instead of a feature arms race—will drive adoption in a large segment that has been chronically underserved. For clinicians, the pitch includes simplified training, seamless data sharing, and remote monitoring tools that aim to keep care teams informed without turning every appointment into a software tutorial.

Manufacturing Readiness Meets Phased Expansion

Behind the patient‑centric narrative is a manufacturing story that investors will recognize as the real test of a commercial pivot. Modular Medical previously converted its manufacturing line to support next‑generation insulin pump cartridges, laying the groundwork for initial capacity that can support around 6,000 users on a scalable, low‑cost platform. Production validation lots have already been reported, and the company has indicated that initial shipments of Pivot pumps would begin by the end of the second quarter of 2026.

The commercialization playbook calls for a phased rollout, initially focused on select, high‑volume endocrinology practices before expanding into broader metropolitan markets by late 2026. Beyond the U.S. launch, Modular Medical is targeting CE mark approval by late 2026 or early 2027, positioning Pivot for entry into European markets once regulatory boxes are checked. Software enhancements—including variable bolus capabilities, improved alarms, and eventual ACE/AID compatibility—are already on the development roadmap, hinting at an iterative upgrade cycle layered onto the core simplicity thesis.

Digital Storytelling: From Clinic to Screen

While the clinical and regulatory arc is familiar, Modular Medical has also turned to digital channels to shape the brand narrative around accessibility and empowerment. The company’s YouTube presence focuses on simplifying diabetes management and highlighting that “everyone” should have access to the superior care that insulin pumps offer, reinforcing the “almost‑pumper” positioning in patient‑friendly language. Patient‑facing content emphasizes everyday scenarios—work, family life, and activity—rather than abstract charts, aligning with Pivot’s promise of intuitive, real‑world use.

On the patient section of its website, Modular Medical details the system and companion app, which together track insulin doses, manage basal schedules, and facilitate data sharing with care teams—all designed to support glycemic goals without overwhelming patients with dashboards. For providers, dedicated content pitches Pivot as a tool to migrate patients off injections “without the learning curve,” positioning clinicians not just as prescribers, but as partners in a smoother therapy transition.

Investor Lens: Optionality In A Multibillion‑Dollar Problem

From an investor’s vantage point, Pivot represents a focused attempt to monetize a very specific gap in diabetes care: adults on multiple daily injections who remain skeptical of traditional pumps yet remain high‑value candidates for improved glycemic control. By targeting this “almost‑pumper” segment with a tubeless, electronic system that trades complexity for consistency, Modular Medical is effectively structuring a call option on broader pump adoption among patients previously deemed too reluctant or underserved.

With real‑world use now underway and a manufacturing base ready for scaled production, the company is moving into the stage where revenue trajectories, retention rates, and clinical outcome data will begin to validate—or challenge—the simplicity‑first thesis. If Pivot can demonstrate durable adoption, better A1C and time‑in‑range metrics, and a compelling value proposition for payers and providers, the platform may evolve from a niche alternative into a mainstream tool for insulin‑dependent adults who quietly wanted better options all along.

Learn More

The Sources

Modular Medical delivers insulin to first patients on Pivot tubeless patch pump – Yahoo Finance
https://finance.yahoo.com/healthcare/articles/modular-medical-delivers-insulin-first-131500247.html
Pivot™ tubeless insulin patch pump – Patient and product information
https://pivotpump.com
Modular Medical, Inc. – YouTube channel (patient stories and product education)
https://youtube.com/@modularmedical?si=wPob6p9qKQNOfUI1
Modular Medical corporate site – MODD1 system and patient resources
https://www.modularmedical.com
Modular Medical – Patients page (how the system works and app overview)
https://www.modularmedical.com/patients

by John F. Heerdink, Jr. June 30, 2026

June 30, 2026 – S&P 500 Logs Best Quarter Since 2020, AI Supercycle Goes Mainstream, & Market Breadth Improves -( $AMAT $AMD $EPRX $FCEL $INTC $IRDM $MU $NVDA $RKLB Rise! )

U.S. equities closed the second quarter of 2026 at or near record highs on Tuesday, June 30, powered by a massive AI‑chip melt‑up, resilient consumer spending, and investors’ willingness to look through macro cross‑currents into 2H26 earnings and rate‑cut potential.

Headline Takeaways – Q2 Ends With AI-Fueled Surge

The Dow Jones Industrial Average climbed to a fresh all‑time high into quarter‑end, underscoring rotation into quality cyclicals alongside megacap tech.
The S&P 500 delivered its strongest quarter since 2020, rising roughly mid‑teens percent, while the Nasdaq Composite rallied north of 20% as AI and semiconductor names led performance.
Market breadth improved in late June, with communication services, consumer discretionary, and information technology all outperforming, while defensives lagged.

Today’s tape reinforced the idea that Q2 2026 was less about “higher for longer” rates and more about “earnings plus AI leverage,” with equity multiples expanding on the back of AI‑infrastructure and AI‑application themes.

Macro Backdrop – Late-Cycle Feel, Early-AI Exuberance

U.S. stocks rallied as geopolitical tension between the United States and Iran showed signs of easing, helping risk appetite and pressuring oil, which remains far below war‑time peaks.
The Japanese yen hovered near a 40‑year low, keeping FX intervention chatter alive and offering a tailwind to exporters but a headwind for imported inflation.
June itself was choppy, with the S&P 500 drifting near flat for the month at times, but the quarter’s performance remained robust as investors bought dips in tech and AI‑exposed names.

Under President Donald Trump’s administration, the policy mix of tax cuts, tariff recalibration, and pressure on energy producers continues to intersect with AI capex and reshoring narratives, creating an environment where earnings and productivity stories can offset macro uncertainty in inflation and geopolitics.

Sector & Thematic Moves – AI Chips, Cloud, and Healthcare

AI Semiconductor Supercycle

An AI‑chip rally across the quarter added roughly $2 trillion in market value to leading U.S. semiconductor players, including Micron Technology (MU), Intel (INTC), and Advanced Micro Devices (AMD).
Applied Materials (AMAT) surged double digits recently as investors leaned into semi‑equipment leverage to AI‑driven foundry and memory spending.
Alphabet (GOOGL), newly in the Dow, jumped sharply as investors rewarded its AI‑enabled ad, cloud, and productivity stack.

This now sets up Q3 as a “proof quarter” for AI‑hardware and AI‑infrastructure: investors will look for MU, INTC, AMD, and AMAT to convert backlog and design wins into durable margin expansion, not just AI‑hype beta.

Cloud & Enterprise AI – AWS Steps Forward

Amazon.com’s cloud arm, Amazon Web Services (AWS), announced a $1 billion commitment to a new Forward Deployed Engineering (FDE) unit, embedding thousands of engineers directly with customers to accelerate AI adoption.
Initial AWS FDE customers include the National Basketball Association, Ricoh, and the National Football League, highlighting a cross‑industry push to operationalize AI agents and production‑grade models.

This move positions Amazon (AMZN) to deepen wallet share in AI transformation budgets, while also signaling that “AI services plus embedded engineers” may become a standard competitive offering across hyperscalers.

AI + Drug Discovery – Anthropic Joins the Hunt

Anthropic, structured as a public benefit company, launched an internal drug discovery program to complement its Claude Science platform, focused on “neglected” diseases that traditional biopharma often overlooks.
Management presented the initiative as a dual mandate: build AI tools for life sciences partners while directly pursuing patient‑centric programs that commercial markets may under‑prioritize.

This announcement is directionally important for biotech investors: it underscores the growing convergence of foundation models and drug discovery workflows, putting companies aligned with AI‑native target ID, molecule design, and trial optimization squarely in the Q3 spotlight.

Nike (NKE) – Q4 2026 Earnings Snapshot

Nike (NKE) reported fiscal Q4 2026 earnings today, offering a lens into global consumer demand, inventory discipline, and DTC versus wholesale channel dynamics. They highlighted:
- Full year revenues were $46.4 billion, flat on a reported basis and down 2 percent on a currency-neutral basis*
- Fourth quarter revenues were $11.0 billion, down 1 percent on a reported basis and down 4 percent on a currency-neutral basis
- Wholesale revenues for the fourth quarter were $6.6 billion, up 4 percent on a reported basis and up 1 percent on a currency-neutral basis
- NIKE Direct revenues for the fourth quarter were $4.1 billion, down 7 percent on a reported basis and down 9 percent on a currency-neutral basis

Index & Sector Performance – End of Quarter Snapshot

Index / Sector	Move in Q2 2026	Narrative Hook
Dow Jones Industrial Average (DJIA)	Record high; strong quarter close at 52,319.20	Quality cyclicals and megacap tech co‑leading.
S&P 500 (SPX)	~15% quarterly gain, best since 2020, closing at 7,499.36.	AI, consumer, and comms services drive multiple expansion.
Nasdaq Composite (IXIC)	~21% quarterly gain, closing at 26,213.72.	AI chips and software lead, tech volatility faded into strength.
Information Technology (XLK)	~1.7% gain in latest session.	Semi and AI infrastructure at the core of Q2 leadership.
Communication Services (XLC)	~3.1% daily jump.	Alphabet and peers repriced on AI monetization.
Consumer Discretionary (XLY)	~2.7% gain.	Nike and other brands watched as rate path and jobs remain key.

These moves collectively reinforce a “risk‑on but selective” Q2 backdrop, where investors favor cash‑generative, AI‑levered platforms and high‑quality cyclicals over defensives and rate‑sensitives.

What’s Next – Set‑Up for Q3 2026

Macro: Markets will trade on incoming inflation prints, labor data, and central‑bank signaling around the timing and magnitude of potential rate cuts into late 2026.
Earnings: The bar is higher for AI‑beneficiaries; investors will demand evidence that MU, INTC, AMD, AMAT, AMZN, GOOGL, and peers can sustain high‑teens‑plus growth and margin resilience beyond Q2’s AI‑rally.
Thematics: Expect continued interest in AI‑drug discovery (Anthropic and biopharma partners), cloud‑delivered AI services (AWS, Alphabet, Microsoft (MSFT)), and transition‑energy plays such as FCEL as capital chases productivity and decarbonization simultaneously.

VP Watchlist Updates

Amwell® (NYSE: AMWL)

Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $9.12.

Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals Inc. (EPRX, $6.61, +.30%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”

Modular Medical, Inc. (NASDAQ: MODD)

Modular Medical, Inc. (NASDAQ: MODD, $4.50), a leader in innovative, patient-centric insulin delivery, today (June 30) announced that the first patients have completed onboarding and training and are now actively using the Pivot™ tubeless insulin patch pump in real-world settings. This milestone marks the transition of the Pivot pump from development into active patient use and represents a significant step in Modular Medical’s commercialization strategy. The Company will now begin collecting real world utilization data and user feedback to support broader adoption and continued product deployment optimization.

Similarweb Ltd. (NYSE: SMWB)

Similarweb Ltd. (NYSE: SMWB, $6.13), a leading digital data and analytics company powering critical business decisions, announced (June 15) that it has surpassed $300 million in Annual Recurring Revenue (ARR) and signed two multi-year enterprise contracts, each representing seven-figure ARR commitments. Collectively, these contracts represent approximately $47 million in Total Contract Value to be recognized over the next three years and were signed during the second quarter of 2026.

NVIDIA (NVDA)

NVIDIA (NVDA) closes at $200.09, +2.63%.

Rocket Lab Corporation (Nasdaq: RKLB)

Rocket Lab Corporation (Nasdaq: RKLB, $97.95, +15.86%), a global leader in launch and space systems and Iridium Communications Inc. (Nasdaq: IRDM, $54.85, +24.21% over the last 5-days) a leading provider of global voice, data, and positioning, navigation, and timing (PNT) satellite services, announced (June 29) they have entered into a definitive agreement under which Rocket Lab will acquire Iridium. Rocket Lab will acquire all the outstanding shares of Iridium common stock for $54 per share in a cash and stock transaction. This represents an enterprise value for Iridium of approximately $8.0 billion.

FuelCell Energy (FCEL) – Clean Power Capital

FuelCell Energy (FCEL, $36.01, +20.84% on Tuesday) secured approximately $49 million in funding, strengthening its balance sheet to support ongoing fuel‑cell and hydrogen‑related project development.
The raise reinforces investor interest in transition‑energy infrastructure even as large‑cap AI and tech dominate the tape, giving FCEL incremental runway to pursue utility and industrial deployments.

The Sources

Yahoo Finance – “Dow hits record, S&P 500 jumps to cap best quarter since 2020 amid massive chip rally”
https://finance.yahoo.com/markets/live/stock-market-today-dow-hits-record-sp-500-jumps-to-cap-best-quarter-since-2020-amid-massive-chip-rally-224823556.html
CNBC – “Stock market today: Live updates” (June 29, 2026)
https://www.cnbc.com/2026/06/29/stock-market-today-live-updates.html
CNBC – “Nike (NKE) Q4 2026 earnings”
https://www.cnbc.com/2026/06/30/nike-nke-q4-2026-earnings.html
CNBC – “AI chip rally in Q2 adds $2 trillion in value to Micron, Intel, AMD…”
https://www.cnbc.com/2026/06/30/ai-chip-rally-in-q2-adds-2-trillion-in-value-to-micron-intel-amd-.html
CNBC – “Anthropic launches AI drug discovery program – Claude Science”
https://www.cnbc.com/2026/06/30/anthropic-launches-ai-drug-discovery-program-claude-science.html
CNBC – “AWS Amazon AI forward deployed engineers” / Reuters AWS coverage
https://www.cnbc.com/2026/06/30/aws-amazon-ai-forward-deployed-engineers.html
Yahoo Finance – “FuelCell Energy secures $49 million”
https://finance.yahoo.com/energy/articles/fuelcell-energy-secures-49-million-113000463.html

by John F. Heerdink, Jr. June 30, 2026

Biotech, Insulin Pumps, & Power Boards: Four Chronic‑Care Plays Quietly Rewriting the Healthcare Script -( $ABVX $LLY $MMED $MODD )

Wall Street’s biotech and medtech set is quietly stitching together a new playbook for chronic disease – one that blends Phase 3 data, insulin hardware, boardroom star power, and China oncology.

Ulcerative Colitis: Abivax Steps Onto Center Stage

French biotech Abivax SA (NASDAQ: ABVX; Euronext Paris: ABVX) has moved from the watch list to the front row with landmark Phase 3 maintenance data in ulcerative colitis for its oral miR‑124 enhancer, obefazimod. The ABTECT maintenance program showed meaningful placebo‑adjusted clinical remission at week 44 across both 25 mg and 50 mg doses, with differences of roughly 39–40 percentage points versus placebo in a tough, moderate‑to‑severe UC population. Notably, the trial met all key secondary endpoints – including endoscopic improvement, endoscopic remission, corticosteroid‑free remission, and sustained disease control – while maintaining a safety profile that, despite cancer cases at higher doses, remains within expected epidemiological ranges for ulcerative colitis. The company is targeting a New Drug Application filing with the U.S. FDA in the fourth quarter of 2026, giving investors a visible regulatory catalyst and a timeline that Wall Street can actually pencil into a model instead of a wish list.

In classic biotech fashion, the stock has already experienced the roller‑coaster – strong data, safety headlines, and a 30‑plus‑percent drawdown as risk‑off short sellers discovered UC epidemiology overnight – yet fundamental analysts continue to frame ABivax as a high‑conviction late‑stage story with optionality beyond the initial indication. For investors, ABVX offers something rare in small‑cap European biotech: Phase 3 data that reads like a de‑risking event, paired with a valuation that still behaves as if the trial were a coin flip.

Diabetes Hardware: Modular Medical Wants to Simplify the Pump

On the other side of the chronic‑care aisle, Modular Medical, Inc. (NASDAQ: MODD) is aiming to do for insulin delivery what the smartphone did for the flip phone – make the older hardware look fussy, over‑engineered, and slightly embarrassing. MODD created Pivot—to simplify diabetes management and ensure more people can access the benefits of insulin pump therapy. With Pivot, they’re building a community where managing diabetes isn’t a burden, but a step toward a healthier, more vibrant life. This is what management calls the “almost‑pumpers” segment: adults who have resisted traditional insulin pumps despite a clear clinical need, an underserved Population of Insulin-Dependent Adults Still Relying on Multiple Daily Injections, a Multibillion-Dollar Market. Today MODD announced that the first patients have completed onboarding and training and are now actively using the Pivot™ tubeless insulin patch pump in real-world settings. This milestone marks the transition of the Pivot pump from development into active patient use and represents a significant step in Modular Medical’s commercialization strategy. The Company will now begin collecting real world utilization data and user feedback to support broader adoption and continued product deployment optimization. By emphasizing intuitive use and cost‑effectiveness, Modular Medical is effectively betting that simplicity – not more bells and whistles – is the moat that finally broadens pump adoption. For more information on the Pivot system, visit the dedicated site: PivotPump.com and YouTube Pivot Insulin Delivery System channel searchable @ModularMedical.

Trading on Nasdaq MODD sits firmly in the small‑cap innovation bucket. For investors, the thesis hinges on whether the company can convert clinician‑level validation and early deployments into commercial traction before larger incumbents either copy the playbook or buy it outright; in diabetes technology, “almost‑pumpers” is both a target demographic and a reminder that capital markets can be just as commitment‑shy.

Boardroom Signal: MiniMed Adds Alcon’s CEO to Its Bench

MiniMed (NASDAQ: MMED), a global diabetes‑technology player, is using its boardroom to send a clear signal about its ambitions by appointing David Endicott – the Chief Executive Officer of Alcon Inc. (NYSE: ALC) – and medtech operator Linnea Burman to its Board of Directors. The move expands MiniMed’s board from nine to eleven members and imports decades of large‑cap healthcare and public‑company experience into a business competing in one of the most strategically crowded therapeutic arenas.

Endicott’s resume reads like a case study in medtech scaling: he joined Alcon as Chief Operating Officer in 2016, became CEO in 2018, and led Alcon’s spin‑out and return to public markets – a journey that most CFOs would describe as “character‑building” and most investors would describe as “value‑creating.” Bringing that experience into MMED’s boardroom suggests MiniMed is thinking in terms of platform positioning, capital markets discipline, and eventual portfolio separation rather than just incremental product launches.

For shareholders, board composition is rarely a near‑term catalyst, but it is a leading indicator of strategic direction; pairing diabetes‑tech expertise with large‑cap eye‑care leadership implies MiniMed sees its runway not just in devices, but in becoming a more fully fledged, investor‑friendly medtech franchise. In a sector where hardware is increasingly judged by its software and data, MMED’s governance upgrades read less like a formality and more like a subtle declaration of intent.

Oncology Scale: Innovent Biologics and Lilly Deepen China Ties

In oncology, Innovent Biologics, Inc. (HKEX: 01801) and Eli Lilly and Company (NYSE: LLY) have recently entered a commercialization agreement that pairs Innovent’s China oncology footprint with Lilly’s global development and brand power. The collaboration covers the commercialization of Lilly’s therapies in China – including the CDK4/6 inhibitor Verzenio (abemaciclib) – leveraging Innovent’s experienced oncology sales team and broad market reach.

Strategically, the deal gives Lilly an on‑the‑ground partner with proven execution in China’s fast‑evolving reimbursement and hospital‑access landscape, while Innovent gains additional high‑profile assets to feed through its commercial infrastructure. In an oncology market increasingly defined by speed to reimbursement and physician mindshare, plugging branded global drugs into a local specialist platform can be far more efficient than attempting to build a full‑scale China organization from scratch.

From an investor’s lens, Innovent gets incremental product depth and potential revenue streams without bearing full development risk, while Lilly enhances the commercial arc of assets that are already core to its global oncology portfolio. For shareholders in both LLY and Innovent, this is yet another data point supporting the thesis that China partnerships have moved beyond simple licensing toward integrated, execution‑heavy collaborations.

Why This Cluster Matters for Investors

Taken together, Abivax’s late‑stage ulcerative colitis data, Modular Medical’s simplified insulin pump push, MiniMed’s board refresh, and the Innovent‑Lilly China oncology tie‑up mark a subtle but important shift in healthcare investing: capital is following platforms that solve chronic‑care friction rather than chasing one‑off headlines. ABVX offers Phase 3‑level de‑risking anchored by a clearly signposted regulatory path; MODD represents hardware simplification aimed at unlocking a reluctant segment of diabetes patients; MMED’s governance moves hint at medtech scaling aspirations; and Innovent‑LLY demonstrate that oncology globalization is increasingly a matter of smart partnership architecture.

For portfolio builders, these stories support a recurring theme: chronic‑disease franchises that can combine credible clinical data, user‑friendly technology, experienced leadership, and regional commercial leverage tend to compound value faster than their press releases suggest. The risk, of course, is that markets will oscillate between enthusiasm and anxiety – as ABVX’s post‑data volatility has already shown – but for investors willing to look beyond the immediate chart, this emerging quartet offers a practical roadmap for where durable healthcare returns may quietly be assembling next.

The Sources

Abivax (ABVX) Phase 3 Maintenance Trial – Abivax (ABVX) Reports Positive Phase 3 Maintenance Trial Results for Obefazimod in Ulcerative Colitis – Yahoo Finance[finance.yahoo]
Modular Medical (MODD) Insulin Pump – Modular Medical Delivers Insulin in First Human Use of MODD1 Pump – Yahoo Finance[finance.yahoo]
MiniMed (MMED) Board Additions – MiniMed Appoints Alcon CEO David Endicott and Linnea Burman to Its Board of Directors – Yahoo Finance[prnewswire]
Innovent Biologics (01801.HK) and Eli Lilly (LLY) – Innovent Biologics and Lilly Enter Into Commercialization Agreement for Verzenio (Abemaciclib) in China – Yahoo Finance[prnewswire]
Abivax ABTECT Maintenance Trial Details – Abivax’s Obefazimod Met Primary Endpoint in Phase III ABTECT Maintenance Trial – Clinical Trials Arena[clinicaltrialsarena]
Abivax Landmark Maintenance Results Press Release – Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results in Ulcerative Colitis[ir.abivax]
Modular Medical MODD1 First Human Use – Modular Medical Announces First Human Use of MODD1 Pump Delivering Insulin – MarketScreener[marketscreener]
Modular Medical Company/Stock Profile – Modular Medical, Inc. (MODD) Stock Price, News, Quote & History – Yahoo Finance[finance.yahoo]
Innovent–Lilly Commercialization Agreement Release – Innovent Biologics and Lilly Enter Into Commercialization Agreement for Verzenio (Abemaciclib) – PR Newswire[prnewswire]

by John F. Heerdink, Jr. June 29, 2026

Needles Out, Pumps In: Modular’s Pivot and Insulet’s Omnipod Seek To Rewrite the Diabetes Playbook -( $MODD $PODD )

Wall Street is quietly drafting a new chapter in diabetes technology, and investors may want to read every line: Modular Medical (NASDAQ: MODD) and Insulet Corporation (NASDAQ: PODD) are positioning tubeless insulin pumps not as gadgets, but as infrastructure for a chronic epidemic that is still very much in expansion mode.

A Growing Epidemic Meets A Hardware Problem

More than 40 million Americans are living with diabetes today, roughly 12% of the U.S. population, and an estimated 1.5 million more are diagnosed every year. Over 2 million Americans live with type 1 diabetes, with insulin not as an option, but as a daily requirement. Yet despite this scale, the hardware story is surprisingly underpenetrated: roughly 4.8 million people in the U.S. require daily insulin, but only about 20% use an insulin pump, leaving the vast majority on multiple daily injections and an addressable, multi‑billion‑dollar gap in pump adoption. This mismatch—high prevalence, low device adoption—is precisely where Wall Street’s attention is starting to migrate, from drugs alone to durable, recurring‑revenue technology platforms.

Modular Medical (MODD): Shipping Simplicity Into

Modular Medical (NASDAQ: MODD) has now moved from promise to physical product, announcing that its Pivot tubeless insulin patch pump starter kits are shipping to multiple endocrinology practices and physician offices for training and patient introduction. Pivot recently secured FDA 510(k) clearance and now enters the U.S. market as only the second fully electronic, tubeless insulin pump available, giving MODD a differentiated seat at a small but strategically important table..

The Pivot pump is purpose‑built for adults with diabetes who are currently on multiple daily injections and have previously balked at traditional pump systems due to cost, complexity, and usability concerns—MODD’s self‑described “almost‑pumpers,” estimated to represent about 70% of insulin‑dependent adults. With a removable two‑part design, a 3 mL reservoir, and no need for battery recharging, the device is engineered to reduce friction at every step, aiming to convert reluctance into adoption and injections into recurring device revenue.

MODD’s plan is intentionally disciplined rather than splashy: full commercial launch will roll out in phases, beginning with select high‑volume endocrinology practices and expanding across metropolitan markets by late 2026, supported by an initial manufacturing capacity of roughly 6,000 users and a scalable low‑cost platform designed for rapid ramp. For investors, that phased strategy reads less like a startup sprint and more like a capital‑efficient call option on broader U.S. pump penetration—and, ultimately, international expansion once CE mark approval is targeted in late 2026 or early 2027.

Insulet (PODD): Boardroom Reinforcements For A Global Tubeless Franchise

Insulet Corporation (NASDAQ: PODD), already the global leader in tubeless insulin pump technology through its Omnipod brand, is leaning into governance and strategic oversight as competition in tubeless pumps heats up. The company recently announced the appointment of Jonathan (“Jay”) Mazelsky as an independent director, effective July 1, 2026, bringing to the board a track record of translating science into commercial solutions that drive durable growth and shareholder value. Insulet’s leadership has framed the addition as part of a larger effort to expand access and further strengthen Omnipod’s leadership position worldwide, at a time when diabetes prevalence continues to climb and device penetration is still far from saturation. With over 40 million Americans living with diabetes and tens of millions more sitting in the prediabetes queue, the addressable pump market is not simply large—it is structurally replenished every year. For PODD shareholders, strengthening the board with commercially minded scientific leadership looks less like window dressing and more like a pre‑emptive move to defend and extend a category that MODD and others are now actively entering.

The Investment Narrative: From Injections To Installed Base

From an investor’s lens, the diabetes device market is evolving from a niche accessory story into an installed‑base, razor‑and‑razor‑blade model tied to a chronic condition with rising prevalence and significant economic impact. Diagnosed diabetes alone carries an estimated annual cost north of $400 billion in the U.S., including more than $300 billion in direct medical expenses—a cost structure that increasingly incentivizes payers and providers to favor technologies that improve adherence and outcomes.

Against this backdrop, MODD’s Pivot aims to convert the 80% of daily‑insulin users still on injections into pump customers by lowering cost and complexity barriers, positioning the company at the front end of underpenetrated demand. Insulet, by contrast, is managing a global, established tubeless franchise, adding governance firepower to maintain Omnipod’s leadership as competition intensifies and as new players assert that “simple, affordable, flexible” pumps can attract hesitant users. In practical terms, that sets up a two‑track narrative: MODD as an emerging commercial‑stage player with high operating leverage to incremental adoption, and PODD as a scaled incumbent using strategic appointments to protect its moat and extend its runway. For investors attentive to secular health trends, both names sit within the same structural theme—the long transition from injections to smart, tubeless, connected delivery—but at very different points along the risk‑reward curve.

Diabetes Tech As A Long‑Duration Theme

With diabetes prevalence climbing from roughly 10% of the U.S. population two decades ago to over 11% today and more than 40 million Americans now living with the disease, the macro trend is not subtle. Each year adds new patients and incremental demand for insulin and delivery technologies, while a large installed base continues to navigate cost, access, and adherence challenges that tubeless pumps aim to mitigate.

The investment question is less whether diabetes technology will grow, and more who will own the most valuable share of that growth: early‑stage innovators like Modular Medical (MODD), targeting “almost‑pumpers” with a simplified tubeless solution now shipping into endocrinology offices, or global leaders like Insulet (PODD), reinforcing boardroom expertise to defend and scale a mature tubeless franchise. In a market where only about one in five daily‑insulin users currently relies on a pump, the runway is long enough to accommodate more than one winner—but not necessarily for the complacent. For investors crafting exposure to diabetes technology, the emerging story is not just about devices; it is about platforms, recurring revenue, and the slow but steady migration of millions of patients from syringes to software‑enhanced, tubeless hardware. As MODD begins its commercial journey and PODD refreshes its strategic bench, the space offers an unusually clear combination of secular growth, underpenetration, and differentiated competitive positioning—a combination that tends to age well in long‑term portfolios.

Learn More

Paul DiPerna, founder of Modular Medical, Inc and legacy inventor of insulin pumps and other medical devices, shares why he created the Pivot™ Insulin Delivery System and potential advantages of Pivot™ compared to daily insulin injections.

The Sources

Modular Medical Announces Shipment of Pivot Tubeless Patch Pumps – Accesswire via Morningstar
https://www.morningstar.com/news/accesswire/1181878msn/modular-medical-announces-shipment-of-pivot-tubeless-patch-pumps[morningstar]
Modular Medical Starts Shipping Pivot Pumps to Doctors’ Offices – StockTitan
https://www.stocktitan.net/news/MODD/modular-medical-announces-shipment-of-pivot-tubeless-patch-q6kcn0c2fej5.html[stocktitan]
Modular Medical Launches Pivot Tubeless Insulin Patch Pump – Drug Delivery Business News
https://www.drugdeliverybusiness.com/modular-medical-launches-pivot-tubeless-pump/[drugdeliverybusiness]
Modular Medical Announces Commercial Availability of Pivot Tubeless Insulin Patch Pump – Access Newswire
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/modular-medical-announces-commercial-availability-of-pi[accessnewswire]
Only 20% Use Insulin Pumps – Modular Medical / Tribe Public CEO Event Note – StockTitan
https://www.stocktitan.net/news/MODD/registration-is-now-open-for-tribe-public-s-ceo-presentation-and-q-a-7758uuxd5eia.html[stocktitan]
Insulet Announces Appointment of Jonathan J. Mazelsky to Its Board of Directors – Insulet Investor Relations
https://investors.insulet.com/news/news-details/2026/Insulet-Announces-Appointment-of-Jonathan-J–Mazelsky-to-its-Board-of-Direc[investors.insulet]
National Diabetes Statistics Report – CDC
https://www.cdc.gov/diabetes/php/data-research/index.html[cdc]
Diabetes in America: Prevalence, Statistics, and Economic Impact – American Diabetes Association
https://diabetes.org/about-diabetes/statistics/about-diabetes[diabetes]
Diabetes Statistics – NIDDK
https://www.niddk.nih.gov/health-information/health-statistics/diabetes-statistics[niddk.nih]
How Many Americans Have Diabetes? – USAFacts
https://usafacts.org/articles/how-many-americans-have-diabetes/[usafacts]
Insulin Statistics: Costs, Usage & Diabetes Rates – SingleCare
https://www.singlecare.com/blog/news/insulin-statistics/[singlecare]

by John F. Heerdink, Jr. June 29, 2026

June 29, 2026 – The Market Climbs, Small Caps Sulk, And Investors Pretend They’re Not Checking Their Phones Every Five Minutes -( $AMWL $GOOG $INTG $IRDM $NVDA $RKLB $SMWB $TSLA Rise! )

U.S. stocks finished broadly higher on Monday, June 29, 2026, with tech leading gains and all major large‑cap benchmarks closing in the green while small caps slipped modestly. Indeed, Wall Street traded in a tight range for much of the day before buyers stepped in, driving a strong close in the S&P 500 and Nasdaq as investors embraced large‑cap growth and AI‑adjacent names. Sentiment improved on headlines that the U.S. and Iran are implementing an interim halt to attacks, even as crude oil’s advance and FX volatility kept macro risks in focus.

S&P 500 (SPX): 7,440.43, up 86.41 points (+1.18%)
Dow Jones Industrial Average (DJIA): 52,182.74, up 306.63 points (+0.59%)
Nasdaq Composite (IXIC): 25,820.14, up 522.53 points (+2.07%)
Russell 2000 (RUT): 3,006.98, down 3.11 points (‑0.10%).

Index Performance And Cross‑Asset Moves

Large‑cap U.S. equities: The S&P 500’s 1.18% gain reflected broad strength across mega‑cap tech, communication services, and select consumer names, consistent with investors rotating back into secular growth after last week’s AI‑driven volatility. The Dow’s 0.59% rise underscored a supportive backdrop for blue‑chip industrials and financials, even as the index’s sector mix shifts with Alphabet’s (GOOG, $351.28, +4.96%) arrival.

Nasdaq and small caps: The Nasdaq’s 2.07% surge highlighted renewed appetite for high‑beta growth, software, and semiconductor names, reinforcing the market’s preference for scalable AI and cloud narratives within the current macro. In contrast, the Russell 2000 slipped 0.10%, signaling lingering skepticism around domestically focused cyclicals and smaller balance sheets in an environment of higher input costs and uneven demand.

Global and commodities: A global gauge of stocks rose as risk assets responded positively to the interim U.S.–Iran peace deal, although oil’s climb reminded investors that geopolitical risk can quickly reprice inflation expectations. U.S. crude settled near 70.41 (+1.7%), with Brent around 72.88 (+1.24%), reinforcing the “higher for longer” operating‑cost narrative for energy‑sensitive sectors..

FX and gold: The yen’s slide to a 40‑year low and gold’s trajectory toward its steepest quarterly drop since 2013 captured the ongoing rotation away from traditional havens and into equities and carry trades. This backdrop keeps central‑bank policy paths and cross‑asset correlations front‑and‑center for allocation decisions into the second half of 2026.

Stock And Sector Highlights

Alphabet Inc. (GOOG, GOOGL): Alphabet officially joined the Dow Jones Industrial Average today, replacing Verizon Communications Inc. (VZ), a move S&P Global described as better reflecting “vibrant sectors” of the U.S. economy. The index rebalance may drive incremental passive and benchmark‑aware flows into Alphabet while slightly reducing mechanical demand for Verizon, further tilting the Dow toward digital platforms and cloud‑AI exposure.

Verizon Communications Inc. (VZ) and BT Group plc (BT): Beyond the index change, BT and Verizon advanced a 50‑50 venture covering their international units with about $4 billion in revenue, underscoring the telco industry’s shift from global expansion toward disciplined, locally focused operations. The structure reflects a continued emphasis on capital efficiency and network monetization rather than footprint‑driven growth.

Tesla Inc. (TSLA): Tesla shares recently reclaimed the $400 level, rising roughly 8.46% to $411.84 on June 29 Eastern Time amid optimism around Q2 deliveries and its broader AI and autonomy roadmap. While not the central macro driver today, TSLA’s move illustrates how “AI‑plus‑hardware” narratives remain powerful in attracting risk capital even after bouts of volatility.

Crypto and regulation: Crypto assets traded defensively as Europe’s MiCA implementation and Spain’s securities regulator signaled strict oversight, contributing to a cautious stance in digital assets relative to traditional equities. For listed exchanges and fintech names, regulatory clarity remains a key valuation driver going into H2 2026.

Macroeconomic And Policy Narrative

Geopolitics and energy: Markets are in a “cautious relief” phase as the interim U.S.–Iran peace deal reduces the probability of near‑term escalation but does not fully remove tail risks for oil and shipping routes. Equities can grind higher in this regime, but any deterioration in headlines could quickly reprice both the commodity complex and volatility.

Inflation and growth: The combination of rising crude, a strong equity bid, and weak gold suggests investors are skewing toward a soft‑landing or “slow‑but‑positive” growth narrative rather than stagflation. That said, the underperformance of small caps versus the S&P 500 and Nasdaq points to continued selectivity and a preference for scale, balance‑sheet strength, and pricing power,

Central banks and FX: The yen’s 40‑year low highlights how far the Bank of Japan’s stance remains from more aggressively tightening peers, sustaining lucrative carry structures and influencing global liquidity conditions. Any sign of policy normalization in Japan would be a significant macro catalyst, with implications for risk assets, EM flows, and sector leadership.

VP Watchlist Updates

Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $9.30, +1.02%..

Eupraxia Pharmaceuticals Inc. (EPRX, $6.59), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”

Modular Medical, Inc. (NASDAQ: MODD, $4.88), a leader in innovative, patient-centric insulin delivery, announced ( June 26) that the Pivot™ tubeless insulin patch pump is now shipping to physician offices for training. Upon completion of training, these pumps will be presented to potential patients in the next few days and weeks. The Company intends to expand the roster of practices that offer Pivot over the coming months. This is another significant milestone in the deployment of Pivot. Modular Medical looks forward to updating the market when these first patients are using the pump to deliver insulin. The Pivot pump is purpose-built for adults with diabetes on daily injections who have faced cost, complexity, and usability barriers with traditional pump systems. This group represents an estimated 70% of insulin-dependent adults who remain on multiple daily injections, a multi-billion-dollar opportunity within the diabetes technology market.

Similarweb Ltd. (NYSE: SMWB, $6.18, +10.36%), a leading digital data and analytics company powering critical business decisions, announced (June 15) that it has surpassed $300 million in Annual Recurring Revenue (ARR) and signed two multi-year enterprise contracts, each representing seven-figure ARR commitments. Collectively, these contracts represent approximately $47 million in Total Contract Value to be recognized over the next three years and were signed during the second quarter of 2026.

NVIDIA (NVDA) closes at $194.97, +1.27%.

Rocket Lab Corporation (Nasdaq: RKLB, $97.95, +15.86%), a global leader in launch and space systems and Iridium Communications Inc. (Nasdaq: IRDM, $54.59, +25.44%) a leading provider of global voice, data, and positioning, navigation, and timing (PNT) satellite services, today announced they have entered into a definitive agreement under which Rocket Lab will acquire Iridium. Rocket Lab will acquire all the outstanding shares of Iridium common stock for $54 per share in a cash and stock transaction. This represents an enterprise value for Iridium of approximately $8.0 billion.

The Sources

Here’s a clean, numbered list of the key sources and links referenced so far, optimized for you to drop into an article, email, or show notes:

Yahoo Finance – “Stock market today: Monday, June 29”
https://finance.yahoo.com/markets/stocks/live/stock-market-today-monday-june-29-224230573.html
CNBC – “Stock futures today, live updates” (June 28–29, 2026)
https://www.cnbc.com/2026/06/28/stock-futures-today-live-updates.html
CNBC – “Stock market today: live updates” (June 29, 2026)
https://www.cnbc.com/2026/06/29/stock-market-today-live-updates.html
Yahoo Finance Video – “Alphabet joins Dow, Verizon & BT strike venture”
https://finance.yahoo.com/video/alphabet-joins-dow-verizon-bt-193230190.html
Reuters – “Breakingviews: BT–Verizon deal puts global telco ghosts to bed”
https://www.reuters.com/commentary/breakingviews/bt-verizon-deal-puts-global-telco-ghosts-bed-2026-06-29/
Reuters – “Stocks adrift, oil up as US–Iran halt renewed attacks”
https://www.reuters.com/world/china/global-markets-wrapup-1-pix-2026-06-29/
TradingKey – “Tesla Stock Rises 5% to Reclaim $400 Mark…”
https://www.tradingkey.com/analysis/stocks/us-stocks/261998552-tesla-q2-delivery-exceeded-expectations-robotaxi-optimus-xai-grok
InvestingNews – “Crypto News: Binance Halts EU Ops After MiCA Setback”
https://investingnews.com/cryptocurrency-market-recap/
WSJ – “Alphabet, Google’s Parent, Is Joining the Dow”
https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-06-23-2026/card/alphabet-google-s-parent-is-joining-the-do

All Posts

A “Goldilocks‑ish” Jobs Report Sets the Macro Stage

Rivian’s Quiet Flex: Execution Over Hype

Similarweb: Turning Data Exhaust into Durable ARR

Modular Medical: From De‑Risking to Deployment

Where the Macro Meets the Micro for Investors

The Sources

Diabetes Tech: Pumps Go Prime Time

From FDA Wins To Revenue Engines

Telehealth Grows Up: HIMS Bets On Longevity

Platform Risk Meets Clinical Credibility

Fintech With A Cape: Investa’s Robin Hood Moment

Options For The Masses, Optionality For Investors

The Common Thread: Ownership, Data, And Stickiness

Where The Opportunity May Reside

The Sources

Market wrap: mixed start to H2

Macro & Fed: Warsh tries to thread the needle

Sector moves and leadership rotation

Single‑stock drivers: META, SpaceX and Lime

Positioning takeaways for investors

VP Watchlist Updates

Amwell® (NYSE: AMWL)

Eupraxia Pharmaceuticals Inc. (EPRX)

Modular Medical, Inc. (NASDAQ: MODD)

Similarweb Ltd. (NYSE: SMWB)

NVIDIA (NVDA)

Rocket Lab Corporation (Nasdaq: RKLB)

The Sources

Key Takeaways For Investors

The Fed’s 2% Line In The Sand

Jobs: Cooling, Not Cracking

Semis Still Steal The Macro Show: TSMC And Lilly

Modular Medical: A Small‑Cap Shot Of Insulin Innovation

Similarweb: Data As A Line Item, Not A Nice‑To‑Have

How To Position Now: Quality Growth, Select Small‑Cap Optionality

The Sources

A Small Cap With Big Ambitions: Modular Medical Tries to Pivot Diabetes Care

The News: FDA Submission Signals a Platform, Not a One‑Off

Why Pivot Exists: Solving for Simplicity, Not Just Sensors

How Pivot Works: A Pump Built for Real Life

Watch the Story: Founder’s Rationale in Focus

Market Context: “Almost Pumpers” as a Structural Growth Theme

The Investment Angle: Optionality in a Small Package

Bottom Line: A “Simple” Pump That Could Complicate the Competitive Landscape

The Sources

Insulin, Simplified: A Commercial Debut With Stakes

From Daily Injections to Push‑Button Control

A Tubeless Bet On the “Almost‑Pumper”

Manufacturing Readiness Meets Phased Expansion

Digital Storytelling: From Clinic to Screen

Investor Lens: Optionality In A Multibillion‑Dollar Problem

Learn More

The Sources

Headline Takeaways – Q2 Ends With AI-Fueled Surge

Macro Backdrop – Late-Cycle Feel, Early-AI Exuberance

Sector & Thematic Moves – AI Chips, Cloud, and Healthcare

AI Semiconductor Supercycle

Cloud & Enterprise AI – AWS Steps Forward

AI + Drug Discovery – Anthropic Joins the Hunt

Nike (NKE) – Q4 2026 Earnings Snapshot

Index & Sector Performance – End of Quarter Snapshot

What’s Next – Set‑Up for Q3 2026

VP Watchlist Updates

Amwell® (NYSE: AMWL)

Eupraxia Pharmaceuticals Inc. (EPRX)

Modular Medical, Inc. (NASDAQ: MODD)

Similarweb Ltd. (NYSE: SMWB)

NVIDIA (NVDA)

Rocket Lab Corporation (Nasdaq: RKLB)

FuelCell Energy (FCEL) – Clean Power Capital

The Sources

Ulcerative Colitis: Abivax Steps Onto Center Stage

Diabetes Hardware: Modular Medical Wants to Simplify the Pump

Boardroom Signal: MiniMed Adds Alcon’s CEO to Its Bench

Oncology Scale: Innovent Biologics and Lilly Deepen China Ties

Why This Cluster Matters for Investors

The Sources

A Growing Epidemic Meets A Hardware Problem

Modular Medical (MODD): Shipping Simplicity Into